Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028042 | 0.97 | CYP2A6 (0.43) | HTR2BCYP2A6HRH3PGRKCNH2 | |
| SCHEMBL5033190 | 0.95 | HRH3 (0.42) | HTR2BCYP2A6HRH3PGRKCNH2 | |
| SCHEMBL5028054 | 0.93 | CYP2A6 (0.46) | CYP2A6HRH3PGRKCNH2MIF | |
| SCHEMBL5032790 | 0.86 | HRH3 (0.55) | HTR2BCYP2A6HRH3KCNH2 | |
| SCHEMBL5034778 | 0.86 | CYP2A6 (0.46) | CYP2A6HRH3PGRMIFCA9 | |
| SCHEMBL2096423 | 0.83 | CYP2A6 (0.43) | CYP2A6HRH3PGRMIFCA9 | |
| SCHEMBL5034855 | 0.83 | HRH3 (0.55) | CYP2A6HRH3KCNH2 | |
| SCHEMBL7494225 | 0.83 | CYP2A6 (0.43) | CYP2A6HRH3PGRMIFCA9 | |
| SCHEMBL5030411 | 0.81 | HRH3 (0.54) | CYP2A6HRH3KCNH2 | |
| SCHEMBL5032985 | 0.79 | HRH3 (0.58) | CYP2A6HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689732-A4 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | UNIV NORTH CAROLINA (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080221191-A1 | Cationic substituted benzofurans as antimicrobial agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-11 | — | — | US | disclosed |
| US-7417158-B2 | Mycobacterium tuberculosis infection; protozoan pathogens; fungal pathogens | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080114047-A1 | Cationic substituted benzofurans as antimicrobial agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-15 | — | — | US | disclosed |
| EP-1689732-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | The University of North Carolina at Chapel Hill (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050197378-A1 | Cationic substituted benzofurans as antimicrobial agents | TIDWELL RICHARD R (US) | 2005-09-08 | — | — | US | disclosed |
| WO-2005055935-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114047-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | HTR2B 3182/4885CYP2A6 4517/4885HRH3 977/4885 |
| US-20050197378-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | HTR2B 3182/4885CYP2A6 4517/4885HRH3 977/4885 |
| US-20080221191-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | HTR2B 3182/4885CYP2A6 4517/4885HRH3 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.